ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TTOO T2 Biosystems Inc

4.22
0.50 (13.44%)
07 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
T2 Biosystems Inc NASDAQ:TTOO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 13.44% 4.22 4.22 4.29 3.7875 3.30 3.41 903,568 00:59:44

T2 Biosystems Announces 2017 First Quarter Financial and Operational Results Release and Conference Call Date

24/04/2017 12:54pm

GlobeNewswire Inc.


T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more T2 Biosystems Charts.

T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2017 first quarter financial and operational results after the market closes on Tuesday, May 2, 2017. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, May 2, 2017, to discuss the financial results and other business developments.

Interested parties may access the live call via telephone by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.

About T2 BiosystemsT2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.

Media Contact:
Matthew McKillip, T2 Biosystems
mmckillip@t2biosystems.com
518-577-3466

Investor Contact:
Tucker Elcock, Teneo Strategy
Tucker.Elcock@teneostrategy.com
212-886-9319

1 Year T2 Biosystems Chart

1 Year T2 Biosystems Chart

1 Month T2 Biosystems Chart

1 Month T2 Biosystems Chart

Your Recent History

Delayed Upgrade Clock